IPO Guru
IPO Guru
Bajaj
S3V Vascular ₹545 ▲ 0.0% 1M
Buy Sell

S3V Vascular Unlisted Shares

S3V Vascular Technologies

Healthcare Medical Devices

S3V Vascular Technologies manufactures minimally invasive cardiovascular devices including balloon catheters, stents, and guide wires, exporting to 60+ countries.

Read the full company profile
Indicative price
As of 23 Oct 2026
₹545 ▲ 0.00% in 1 month
Dealer quotes: ₹535 – ₹545 across 3 dealers
Key facts

S3V Vascular share details

Lot size
100 shares
Min. investment
₹54,500
Face value
₹10
Implied market cap
₹1,059 Cr
Shares outstanding
19,434,502
Headquarters
Mysuru, Karnataka
Website
s3vvascular.com
ISIN
INE0HGT01012
CIN
U33112KA2011PLC059915
Lock-in after IPO
6 months
Price history

S3V Vascular share price chart

1Y change
+45.33%
High
₹565
Low
₹350

Indicative off-market dealer quotes, not exchange prices. A flat stretch means the quote did not change on those days.

About

About S3V Vascular

S3V Vascular Technologies Pvt Ltd is a Coimbatore-based medical device manufacturer specialising in cardiovascular and peripheral vascular intervention products. The company manufactures balloon catheters, PTCA guide wires, coronary stents, and microcatheters, supplying to hospitals and distributors in 60+ countries. S3V is one of the few Indian companies with full in-house R&D and manufacturing for complex vascular devices. The company has CE, ISO 13485, and US FDA registrations. With India's medical device sector growing at 15%+ CAGR and global demand for affordable interventional cardiology products rising, S3V is well-positioned for expansion.
IPO outlook

When is the S3V Vascular IPO?

Anticipated
FY26-27
S3V Vascular has explored a mainboard IPO as part of its growth capital strategy. The global vascular devices market and India's expanding export opportunities make this an attractive listing. Niche medical device companies tend to command high valuations post-listing.

Strengths

  • Focused on one clear area: the website lists five cardiovascular products (3V SIRIS, 3V NEIL, 3V Krome, 3V PAULO, 3V XTRA) plus a critical care product, 3V AGILE.
  • The company reports a clinical study of 250 patients over 2 years for its 3V SIRIS stent, with 0% stent thrombosis.
  • In the company's own comparison, 3V SIRIS shows 6.8% uncovered stent struts at 4 months against 17.5% for a US FDA approved everolimus stent.
  • 3V SIRIS uses a polymer that the company says degrades 100% in 6 weeks, leaving a bare metal stent, a design aimed at long-term safety.
  • The stent is offered in diameters from 2.25 mm to 4.00 mm and in 7 lengths from 10 mm to 38 mm, which covers a wide range of procedures.

Risks

  • No annual report or financial statements are available from the company's website, so revenue, profit, debt and cash flow cannot be checked here.
  • The clinical results quoted above come from the company's own materials and are not independently confirmed in the documents we hold.
  • The business depends on cardiovascular devices, so a problem with one product such as the 3V SIRIS stent could hit the whole company.
  • Medical devices are tightly regulated, and any change in approvals, quality norms or reimbursement rules can affect sales.
  • It competes in stents against larger and better known makers, including US FDA approved products that it compares itself with.
  • Unlisted shares trade off the exchange at indicative prices of about ₹545, with no regulated price discovery and limited liquidity.
  • No IPO date is announced, and an unlisted company may never list on the timeline buyers expect.
Ready to invest?
CDSL · NSDL T+1 SETTLEMENT NO FEE

Buy or sell S3V Vascular unlisted shares

Get a live quote on WhatsApp in under 60 seconds. Current price ₹545. Shares are delivered to your own demat in 24–48 hours, never to a custodian.

Indicative off-market price, not an exchange quote. Read the disclaimer.

Buy S3V Vascular Sell S3V Vascular
FAQs

S3V Vascular unlisted shares: common questions

Important disclaimer

Unlisted shares are not traded on stock exchanges. Prices shown are indicative and based on off-market transactions; they may differ from eventual listing or future market prices. Exit liquidity depends on counter-party availability. SEBI mandates a 6-month lock-in on pre-IPO shares post-listing. Gains held beyond 24 months are taxed at 12.5% LTCG (no indexation). IPO Guru is not a SEBI Registered Investment Advisor. Information here is for general awareness, not personalised investment advice. Please consult your tax advisor before investing.

Share